



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Arlene H. Sharpe et al.

Serial No.: 08/702,525

Filed: February 7, 1997

For: NOVEL FORMS OF T CELL
COSTIMULATORY MOLECULES AND USES
THEREFOR

Attorney Docket No.: BWI-120CPUS

Group Art Unit: 1644

Examiner: P. Gambel

17/c
D.J.G
6/15/99
(NB)
RESPONSE UNDER 37 CFR 1.116
- EXPEDITED PROCEDURE
EXAMINING GROUP 1644


Assistant Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

June 8, 1999
Date of Signature and of Mail Deposit

By:


DeAnn F. Smith
Reg. No. 36,683
Attorney for Applicants

AMENDMENT AND RESPONSE AFTER FINAL

Dear Sir:

This Amendment and Response is being filed in response to the final Office Action dated December 8, 1998 (Paper No. 14). A separate request for an appropriate extension of time and Notice of Appeal is being filed concurrently herewith. In response to the Action, please amend the application as follows:

In the claims:

Please amend the claims as follows:

9. (Twice Amended) An isolated nucleic acid molecule encoding a B7-1 or B7-2 protein which binds CD28 or CTLA4 and ~~which is an alternative splice form of a transcript of a~~ B7-1 or B7-2 T cell costimulatory ~~molecule~~ gene having at least one first exon encoding a B7-1 or B7-2 first cytoplasmic domain comprising a nucleotide sequence selected from